A Preoperative Biological Trial of Cetuximab, Dasatinib or the Combination in Colorectal Cancer Patients with Resectable Liver Metastases
Phase of Trial: Phase 0
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Cetuximab (Primary) ; Dasatinib (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Biomarker; Pharmacodynamics
- Acronyms SPORE
- 10 Jun 2017 Biomarkers information updated
- 12 Jan 2010 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
- 12 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.